Brief: Kaleido Biosciences Reports Third Quarter 2021 Financial Results

Kaleido Biosciences

01/11/2021 11:36

Nov 1 (Reuters) - Kaleido Biosciences Inc  KLDO.O :
    * KALEIDO BIOSCIENCES REPORTS THIRD QUARTER 2021 FINANCIAL
RESULTS
    * Q3 LOSS PER SHARE $0.54
    * REMAIN ON TRACK TO INITIATE PHASE 2 CLINICAL TRIALS OF
KB109 IN
COPD AND KB295 IN UC IN FIRST HALF 2022
    * AS OF SEPTEMBER 30, 2021, COMPANY REPORTED CASH AND CASH
EQUIVALENTS OF $55.7 MILLION AND HAS CASH RUNWAY INTO Q2 OF 2022
    * Q3 EARNINGS PER SHARE VIEW $-0.54 -- REFINITIV IBES DATA

Source text for Eikon:  ID:nGNX6TCWlh 
Further company coverage:  KLDO.O 

 ((Reuters.Briefs@thomsonreuters.com;))